Drug Trial Radar · NCT06602219
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Oct 25, 2024
Primary completion
Jul 24, 2025
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
LY4100511Drug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo)Time frame: Week 12
Locations
58 sites in 7 countries. Site status is shown where the registry gives one.
Cahaba Dermatology Skin Health Center
Birmingham, Alabama
Dermatology Trial Associates
Bryant, Arkansas
Zenith Research, Inc.
Beverly Hills, California
First OC Dermatology Research Inc
Fountain Valley, California
Center for Dermatology Clinical Research
Fremont, California
Dermatology Research Associates
Los Angeles, California
Clinical Science Institute
Santa Monica, California
Driven Research
Coral Gables, Florida
Direct Helpers Research Center
Hialeah, Florida
Renstar Medical Research
Ocala, Florida
GCP Global Clinical Professionals, LLC
St. Petersburg, Florida
ForCare Clinical Research
Tampa, Florida
Endeavor Clinical Trials Center - Dermatology - Skokie
Skokie, Illinois
Lawrence J Green, M.D, LLC
Rockville, Maryland
Center for Clinical Studies, LTD.LLP
Webster, Texas
Interior Dermatology Centre - Probity - PPDS
Kelowna, British Columbia, Canada
Skin Care West
Nanaimo, British Columbia, Canada
Simcoderm Medical & Surgical Dermatology Centre
Barrie, Ontario, Canada
Dermatrials Research Inc.
Hamilton, Ontario, Canada
Lovegrove Dermatology - Probity - PPDS
London, Ontario, Canada
DermEffects - Probity - PPDS
London, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
DermEdge Research
Mississauga, Ontario, Canada
Pratia Pardubice a.s. - PRATIA - PPDS
Pardubice, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Pratia Prague s.r.o. - PRATIA - PPDS
Prague, Czechia
Kozni ambulance Fialova, s.r.o. - CRC - PPDS
Prague, Czechia
Clintrial s.r.o.
Prague, Praha 10, Czechia
Universitätsklinikum Carl Gustav Carus an der TU
Dresden, Germany
MensingDerma Research GmbH
Hamburg, Germany
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Praxis Dr. med. Virgil-Oreste Mihaescu Facharzt fr Dermatologie und STD
Augsburg, Bavaria, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany
Gyongyosi Bugat Pal Korhaz
Gyöngyös, Hungary
MedMare Bt
Veszprém, Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hajdú-Bihar, Hungary
Allergo-Derm Bakos Kft
Szolnok, Jász-Nagykun-Szolnok, Hungary
Igarashi Dermatological Clinic
Tokyo, Japan
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.